

Rein Therapeutics shares rise after the FDA lifts clinical hold on its Phase 2 RENEW trial for idiopathic pulmonary fibrosis treatment LTI-03.
You can purchase shares of Rein Therapeutics (NASDAQ:RNTX) through any online brokerage.
Other companies in Rein Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Rein Therapeutics has a consensus price target of $6.00.
The stock price for Rein Therapeutics (NASDAQ: RNTX) is $0.521 last updated November 16, 2026 at 7:03 AM EST.
There are no upcoming dividends for Rein Therapeutics.
Rein Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Rein Therapeutics.
Rein Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03,...